About faCellitate
faCellitate is a company based in Mannheim (Germany) founded in 2019 by Simon Widmaier. faCellitate has raised $3.67 million across 1 funding round from investors including Sarstedt, Chemovator and High-Tech Gründerfonds. The company has 50 employees. faCellitate offers products and services including BIOFLOAT™ and BIOINSTRUCT™. faCellitate operates in a competitive market with competitors including Neogen, LGC, RareCyte, seqWell and Paragon Genomics, among others.
- Headquarter Mannheim, Germany
- Employees 50
- Founders Simon Widmaier
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website facellitate.com
- Social LinkedIn X
- Legal Name Chemovator Gmbh
- Total Equity Funding$3.67M (USD)
in 1 rounds
- Latest Funding Round$3.67M (USD), Seed
Sep 2022
- InvestorsSarstedt
& 4 more
- Employee Count50
Products & Services of faCellitate
faCellitate offers a comprehensive portfolio of products and services, including BIOFLOAT™ and BIOINSTRUCT™.
Plates for forming uniform spheroids in 3D cell culture.
Coating for optimized human induced pluripotent stem cell culture.
Funding Insights of faCellitate
faCellitate has successfully raised a total of $3.67M through 1 strategic funding round. The most recent funding activity was a Seed round of $3.67 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.67M
- Total Rounds 1
- Last Round Seed — $3.67M
- First Round $3.67M
(Sep 2022)
- Investors Count 5
All 1 funding rounds of faCellitate with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $3.67M | Seed | – | Sarstedt, Chemovator |
5 investors in total: 5 institutional.
Investors in faCellitate
faCellitate has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Sarstedt, Chemovator and High-Tech Gründerfonds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | chemovator.com | - | |
Early-stage investments are made in high-tech startups by HTGF. | – | htgf.de | Bonn, Germany | |
Provides a suite of products designed for diagnostic and medical laboratories. | 1961 | sarstedt.com | Sarstedt, Germany | |
Manages convertible bond portfolios for investment participation and diversification. | 2019 | arveam.ch | Zurich, Switzerland | |
Recruitment and staffing services are provided by r3 Consultant. | – | r3consultant.com | Pune, India |
Investor details for faCellitate
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of faCellitate
3 people are tracked at faCellitate (3 in leadership); the tracked headcount is 50.
| Name | Role | Group |
|---|---|---|
Simon Widmaier | Co-Founder & Managing Director | Leadership |
Christoph Petry | CEO & MD | Leadership |
Roman Reischl | Co-Founder und Beirat | Leadership |
Complete people profiles for faCellitate
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of faCellitate
2 dated milestones of faCellitate across 3 years, from founding to its latest funding, stage changes and deals.
- Founded faCellitate is founded.
- Funding First funding round of $3.7M.
Competitors of faCellitate
faCellitate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neogen, LGC, RareCyte, seqWell and Paragon Genomics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing | |
| lgcgroup.com | 1842 | Teddington, United Kingdom | – | 901 | Molecular biology reagents and services are supplied to biotech industries. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| seqwell.com | 2014 | Beverly, United States | $24.51M | 30 | NGS-based reagents and kits are supplied for life sciences research. | |
| paragongenomics.com | 2015 | San Francisco, United States | $8M | 26 | Provider of technologies and solutions genomic research and precision medicine | |
| biotangents.co.uk | 2015 | Edinburgh, United Kingdom | $5.62M | 13 | Veterinary diagnostics products are developed for bovine viral diarrhea testing. | |
| novacyt.com | 2005 | Velizy Villacoublay, France | – | – | Developer of cytology instruments and consumables for oncology and infectious disease | |
| genomtec.com | 2016 | Wroclaw, Poland | $4.38M | – | Handheld POC devices for nucleic acid testing are provided. | |
| sequenta.com | 2008 | San Francisco, United States | $43.46M | 58 | Immuno-sequencing products are developed for disease diagnostics and treatment. | |
| hyris.net | 2014 | London, United Kingdom | $2.84M | 14 | Integrated genetic testing platform with cloud-based analysis is provided. |
Detailed competitors of faCellitate
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of faCellitate
The website of faCellitate (facellitate.com) receives about 32K visits a month.
- Monthly visits32K
▲ 13.9% vs previous month
Websites whose visitors overlap most with faCellitate. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
 upbiotech.wordpress.com | upbiotech.wordpress.com | 100% | – | #12,025,372 | – |
biotrend.com | biotrend.com | 96% | – | #4,074,352 | – |
| crownbio.com | 94% | 77K | #441,040 | View details | |
biotechreality.com | biotechreality.com | 90% | – | #2,408,136 | – |
| integra-biosciences.com | 86% | – | #432,153 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for faCellitate
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Facellitate
Complete news archive for faCellitate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to faCellitate
10 companies that operate in the same segment as faCellitate (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about faCellitate
faCellitate was founded in 2019 and raised its 1st funding round 3 years after it was founded.
faCellitate is headquartered in Mannheim, Germany. It is registered at Mannheim, Baden-wurttemberg, Germany.
Christoph Petry is the current CEO of faCellitate.
faCellitate is a funded company, having raised a total of $3.67M across 1 funding round to date. The company's 1st funding round was a Seed of $3.67M, raised on Sep 2022.
faCellitate has 50 employees.
faCellitate was founded in 2019 in Mannheim, Germany, focusing on the biotechnology sector. Cell technologies and regenerative medicine solutions are developed, with operations centered on 3D cell culture products. Spheroid coatings and defined bio-interfaces are supplied, alongside ready-to-use 96-well plates known as BIOFLOAT. Polymer solutions are utilized to adapt cell culture setups into synthetic, biologically functional environments for research applications.
faCellitate's top competitors include Neogen, Paragon Genomics and Biotangents.
faCellitate offers BIOFLOATâ„¢ and BIOINSTRUCTâ„¢.
faCellitate has 5 investors. Key investors include Sarstedt, Chemovator, High-Tech Gründerfonds, Arve Asset Management, and r3 Consultant.
faCellitate operates through Chemovator Gmbh.